CorMedix Inc. (CRMD)

NASDAQ: CRMD · IEX Real-Time Price · USD
3.54
-0.02 (-0.56%)
At close: Dec 5, 2023, 4:00 PM
3.52
-0.02 (-0.56%)
After-hours: Dec 5, 2023, 7:40 PM EST
-0.56%
Market Cap 188.55M
Revenue (ttm) 29,702
Net Income (ttm) -39.79M
Shares Out 54.81M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 509,751
Open 3.60
Previous Close 3.56
Day's Range 3.50 - 3.63
52-Week Range 2.57 - 6.09
Beta 1.86
Analysts Strong Buy
Price Target 14.60 (+312.43%)
Earnings Date Nov 14, 2023

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly know... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 25, 2010
Employees 40
Stock Exchange NASDAQ
Ticker Symbol CRMD
Full Company Profile

Financial Performance

In 2022, CorMedix's revenue was $65,408, a decrease of -65.74% compared to the previous year's $190,936. Losses were -$29.70 million, 5.29% more than in 2021.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price forecast is $14.6, which is an increase of 312.43% from the latest price.

Price Target
$14.6
(312.43% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

CorMedix Inc. Announces Partnership With The Leapfrog Group

– CorMedix to advocate for patient safety and infection prevention as part of  Leapfrog's Partners Advisory Committee

1 day ago - GlobeNewsWire

CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

– First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. 15, 2023 (GL...

20 days ago - GlobeNewsWire

U.S. FDA approves CorMedix's antimicrobial drug

The U.S. Food and Drug Administration (FDA) on Wednesday approved CorMedix's antimicrobial drug that aims to reduce catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, th...

20 days ago - Reuters

CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

21 days ago - GlobeNewsWire

CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023

BERKELEY HEIGHTS, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

4 weeks ago - GlobeNewsWire

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

7 weeks ago - GlobeNewsWire

CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

2 months ago - GlobeNewsWire

CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology

BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

3 months ago - GlobeNewsWire

CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference

BERKELEY HEIGHTS, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

3 months ago - GlobeNewsWire

CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath

BERKELEY HEIGHTS, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

3 months ago - GlobeNewsWire

CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

4 months ago - GlobeNewsWire

CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

5 months ago - GlobeNewsWire

CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

5 months ago - GlobeNewsWire

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

BERKELEY HEIGHTS, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

5 months ago - GlobeNewsWire

Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections

BERKELEY HEIGHTS, N.J. , June 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

6 months ago - GlobeNewsWire

Cormedix Inc. To Present At The Jefferies Healthcare Conference

BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

6 months ago - GlobeNewsWire

CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath

BERKELEY HEIGHTS, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

7 months ago - GlobeNewsWire

CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023

BERKELEY HEIGHTS, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

7 months ago - GlobeNewsWire

CorMedix Inc. to Participate in Two Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

7 months ago - GlobeNewsWire

CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath

BERKELEY HEIGHTS, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

7 months ago - GlobeNewsWire

Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

8 months ago - GlobeNewsWire

CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Conference Call Scheduled for Today at 8:30 a.m. Eastern Time

8 months ago - GlobeNewsWire

Cormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update on March 30, 2023

BERKELEY HEIGHTS, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

9 months ago - GlobeNewsWire

CorMedix Inc. Announces Regulatory and Manufacturing Updates

BERKELEY HEIGHTS, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a...

9 months ago - GlobeNewsWire

CorMedix Inc. Announces Promotions in Commercial and Tech Ops

BERKELEY HEIGHTS, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an...

11 months ago - GlobeNewsWire